In patients with muscle wasting, NYHA functional class III symptoms were more frequent (53% vs. 26%), and the proportion of patients with diabetes (45% vs. 25%) and patients on mineralocorticoid receptor antagonists (53% vs. 34%) were higher than those in patients without muscle wasting. This evidence concerns the gene NR3C2 and diabetes mellitus.